Pharma & Biotech Industry Analysis, from Thought Leaders
Refine Search
Pharmaceutical
The obesity drug market has experienced a seismic shift in recent years, with Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Mounjaro (tirzepatide) revolutionizing the way the condition is treated. 11 April 2025
Pharmaceutical
Pain is good. Or finding non-opioid ways to manage it is good, if Latigo Biotherapeutics’ $150 million March fundraise is anything to go by. 10 April 2025
Pharmaceutical
In this week’s podcast, we welcome Ido Peleg, CEO and Co-Founder of Yonalink, who provides insights into the current and future state of the clinical trial industry. 11 March 2025
Pharmaceutical
In this episode, we’ll take a look at the role of Japanese pharmaceutical groups in the UK, with Jackie Davis, general manager at Astellas Pharma. 24 February 2025
Biotechnology
Marking World Cancer Day 2025, this week's Executive Q&A is with Diego Santoro, General Manager & Head of International Region at Gilead and Kite Oncology. Mr Santoro outlines the company’s efforts to expand access to innovative CAR T-cell therapies in the Middle East. 8 February 2025
Biotechnology
The 90 million euros ($94 million) raised by Orbis Medicines in a series A round was not January’s biggest venture investment by a long stretch. That honor belonged to the whopping $410 million netted by UK obesity group Verdiva Bio, but what Orbis’s VC round does show is the growing interest in macrocyclics as a drug class. 6 February 2025
Pharmaceutical
A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases. 4 February 2025
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Pharmaceutical
For many in the life sciences, the year gone by has been marked by volatility across a range of metrics, as political and economic disruptions threaten to upend the standard operating model. 30 December 2024
Biotechnology
Pfizer (NYSE: PFE) emerged as a global hero during the COVID-19 pandemic, delivering critical medicines at unprecedented speed and saving millions of lives worldwide. 6 December 2024
Pharmaceutical
A Feature on M&A, licensing, and partnership tapping into AI’s potential to improve drug development. 2 December 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Pharmaceutical
Gross domestic product (GDP) in Japan is about $5 trillion, and the country’s pharmaceutical market is one of the largest in the world, with figures from the Ministry of Health, Labour and Welfare (MHLW) indicating a market value of about $95 billion, including non-prescription medications. 28 June 2019
Pharmaceutical
Now that the warming Spanish sun has gone down on EULAR 2019, it’s worth considering what emerged of note from some of rheumatology’s leading players at the event in Madrid. 20 June 2019
Biotechnology
The flags have been furled, poster boards packed away, and ASCO planners are already getting ready for another year. Now, before attention turns to the next major event, we recap some of the key highlights and learnings from the industry’s preeminent cancer conference. 17 June 2019
Biotechnology
Despite a perceived lack of innovation that has moved the needle in the last five years, rheumatology remains a massively lucrative sector in which many of the world’s biggest pharma companies continue to earn the largest slice of their revenue. 7 June 2019
Pharmaceutical
“If Congress weakens patent laws, patients may never benefit from new treatments or cures." 30 May 2019
Biotechnology
It’s ASCO time again. The annual meeting of the American Society of Clinical Oncology (ASCO) is now almost upon us, with the event due to start in Chicago on Friday, May 31. 22 May 2019
Pharmaceutical
In a previous incarnation, Boehringer Ingelheim chief financial officer Michael Schmelmer spearheaded a bold approach to innovation which could bear digital fruit for the 130 year-old family-owned drugmaker. 10 May 2019
Biotechnology
Thankfully, the growing anti-microbial resistance (AMR) crisis is now getting some major headlines and airtime, so that even many lay people are getting a good grasp of the issues at the heart of this global priority. 2 May 2019
Pharmaceutical
The Pharmaceutical Price Regulation Scheme (PPRS) is dead; long live the Voluntary Scheme for Branded Medicines Pricing and Access (Voluntary Scheme)! 16 April 2019
Pharmaceutical
Representatives from pharmacy benefit managers (PBMs) were the latest to be grilled by lawmakers in Washington DC on Tuesday. 10 April 2019
Pharmaceutical
Judging which companies are topping the oncology research charts in any given quarter or year can be highly subjective, but sometimes drugmakers present a series of new findings at once that make their activities hard to ignore. 22 March 2019
Generics
Research shows some 79% of the American public view the cost of prescription drugs as unreasonable, and lawmakers and regulators are increasingly convinced the industry charges too much for its products. 8 March 2019
Pharmaceutical
“Everyone in the ecosystem recognizes that there's going to a lot of innovations coming forward in the next years and those need to get to patients.” 3 March 2019
Pharmaceutical
Japan has long been regarded as a pharma market with unique challenges where the local knowledge of a domestic partner is essential. 23 February 2019
Pharmaceutical
With a matter of weeks to go until the UK is due to leave the European Union, negotiations between warring factions in the British political establishment threaten to derail any prospect of a staged, sensibly managed exit process. 15 February 2019
Pharmaceutical
February 28th is World Rare Disease Day - a day to increase awareness of rare diseases and their impact on those affected. We take this opportunity to provide an overview of five of the rarest diseases in the world and to delve into what pharma must do to progress this therapeutic field further. 5 February 2019
Pharmaceutical
Love it or loathe it, the Institute for Clinical and Economic Review (ICER) is not about to go away. 25 January 2019
Pharmaceutical
Pipelines are the future of pharma, providing an indication of which patients, companies and shareholders will benefit from the next generation of cures and treatments. 24 January 2019
Generics
With around 1.3 billion residents, India is home to just a fraction fewer people than China, the world’s most populous nation. 10 January 2019
Pharmaceutical
Predicting a year in pharma is difficult at the best of times, but in an era of enormous uncertainty – with politics in established markets as impulsive as it is divisive – it's hard to know what drugmakers will have to deal with in 2019, and how their strategies will play out. 20 December 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze